Get the Stockscreener App
3.03
4.42%
-0.14
Myriad Genetics Inc stock is traded at $3.03, with a volume of 1.55M.
It is down -4.42% in the last 24 hours and down -49.83% over the past month.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
See More
Previous Close:
$3.17
Open:
$3.17
24h Volume:
1.55M
Relative Volume:
0.82
Market Cap:
$289.82M
Revenue:
$829.00M
Net Income/Loss:
$-399.90M
P/E Ratio:
-0.7021
EPS:
-4.3159
Net Cash Flow:
$-23.20M
1W Performance:
-7.06%
1M Performance:
-49.83%
6M Performance:
-32.52%
1Y Performance:
-48.56%
1-Day Range:
$3.01
$3.18
1-Week Range:
$3.01
$3.325
52-Week Range:
$2.74
$8.59
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, NTRA, IDXX, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
3.03 | 308.95M | 829.00M | -399.90M | -23.20M | -4.3159 |
TMO
Thermo Fisher Scientific Inc
|
588.29 | 222.96B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
202.45 | 144.67B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
309.93 | 45.54B | 2.50B | -226.32M | 71.51M | -1.6412 |
IDXX
Idexx Laboratories Inc
|
550.96 | 44.95B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
148.53 | 41.87B | 7.23B | 1.41B | 1.09B | 4.979 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-21-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| May-08-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-09-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-12-25 | Initiated | Craig Hallum | Buy |
| Dec-10-24 | Initiated | UBS | Neutral |
| Dec-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Underperform |
| May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-21-23 | Resumed | Piper Sandler | Neutral |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Underweight |
| May-23-23 | Upgrade | Goldman | Sell → Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-06-22 | Initiated | Stephens | Equal-Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Sell |
| Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
| Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-12-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Needham | Strong Buy |
| Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
| Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-29-18 | Initiated | Goldman | Sell |
| Jan-22-18 | Reiterated | Barclays | Equal Weight |
| Jan-05-18 | Initiated | BTIG Research | Buy |
| Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
| Aug-09-17 | Reiterated | Barclays | Equal Weight |
| Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
| Jan-18-17 | Initiated | Deutsche Bank | Sell |
| Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
Myriad Genetics (MYGN): Glenview Capital and Larry Robbins report exit from stake - Stock Titan
Myriad Genetics (MYGN): Vestal Point Capital discloses 6.1% stake in 13G filing - Stock Titan
Myriad Genetics Faces Multiple Investor Investigations - stl.news
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
Dimensional Fund Advisors LP Reduces Stake in Myriad Genetics, Inc. $MYGN - MarketBeat
Myriad Genetics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Assenagon Asset Management S.A. Reduces Holdings in Myriad Genetics, Inc. $MYGN - MarketBeat
3 Healthcare Stocks with Open Questions - Yahoo Finance
Price-Driven Insight from (MYGN) for Rule-Based Strategy - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, In - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Reach Out - ACCESS Newswire
Myriad Genetics (MYGN) Securities Investigation NoticeLevi & Korsinsky - PR Newswire
Myriad Genetics And 2 Other Promising Penny Stocks For Your Watchlist - simplywall.st
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law - FinancialContent
Myriad Genetics (NASDAQ:MYGN) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Myriad Genetics Inc (MYD.HA) stock price, news, quote and history - Yahoo Finance Australia
State Street Corporation (NYSE: STT) discloses 5.3% holding in Myriad Genetics - Stock Titan
Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating Through a Challenging Landscape with 69.36% Potential Upside - directorstalkinterviews.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Myriad Genetics (MYGN) - globenewswire.com
Myriad Genetics (NASDAQ:MYGN) Lowered to Strong Sell Rating by Zacks Research - MarketBeat
MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP - GlobeNewswire
MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN) - Business Wire
MYGN SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Myriad Genetics - Morningstar
Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel - GlobeNewswire
Myriad Genetics, Inc. Stock 12‑Month Price Target Cut to $5.34, Implies 87% Upside - TradingView
Myriad Genetics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Myriad Genetics (MYGN) - PR Newswire
MYGN Slides As Myriad Genetics Slashes 2026 Revenue Outlook - timothysykes.com
Myriad Genetics (MYGN) Missed Q2 And Cut Guidance, Is It Still 54% Below Fair Value? - Yahoo Finance
MYGN Stock Slides As Myriad Genetics Slashes 2026 Outlook - timothysykes.com
Myriad Genetics: Strong Oncology Demand, But Monetization Breaks Down (NASDAQ:MYGN) - Seeking Alpha
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability - The Manila Times
MYRIAD GENETICS ($MYGN) Releases Q2 2026 Earnings - Quiver Quantitative
Myriad: Q2 Earnings Snapshot - KVUE
Wells Fargo Maintains Myriad Genetics(MYGN.US) With Hold Rating, Maintains Target Price $5.5 - Moomoo
$Myriad Genetics (MYGN.US)$ Snag a bargain 🤣 - Moomoo
Myriad Genetics (MYGN) Reports Q2: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Myriad Genetics rebuilt its AI platform after costs ballooned. Now, it can process documents in seconds. - Business Insider
Myriad Genetics Inc (MYGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Myriad Genetics Inc (MYGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Orbimed Advisors LLC Purchases Shares of 125,000,000 Myriad Genetics, Inc. $MYGN - MarketBeat
TradingKey - TradingKey
MYGN|Myriad Genetics Inc|Price:5.610|Chg%:-0.090 - TradingKey
Myriad Genetics Inc (MYGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Myriad Genetics (MYGN) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Myriad Genetics, Inc. (MYGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Myriad Genetics, Inc. (MYGN) stock price, news, quote and history - Yahoo Finance UK
Myriad Genetics, Inc. Stock 12‑Month Price Target Cut to $6.14, Implies 8% Upside - TradingView
Myriad Genetics Inc (MYGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):